A Study of LY3305677 in Participants With Obesity Or Overweight

NCT05623839 · Completed

Last updated 2026-05-28

This study tests the safety of the experimental drug LY3305677 in adults who are overweight or have obesity.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind basic-science study

Participants 32 people

Who can join Ages 18–70 · all sexes Healthy volunteers accepted.

Timeline Started 2022-11 · est. completion 2023-06

Where 3 sites · United States

What this study is testing ClinicalTrials.gov NCT05623839 ↗

Description as written by the study sponsor.

The main purpose of this study is to learn about the safety and tolerability of LY3305677 when given to participants with obesity or overweight. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive injections of LY3305677 or placebo given just under the skin. For each participant, the study will last about approximately 28 weeks.

Treatments tested

LY3305677 Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Sponsor	Eli Lilly and Company
Conditions studied	Overweight, Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05623839 ↗